Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.
Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.
Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8.
View in:
PubMed
subject areas
Anti-Inflammatory Agents, Non-Steroidal
Biomarkers
Cytokines
Etanercept
Female
Humans
Immunoglobulin G
Injections, Subcutaneous
Interferon-gamma
Interleukin-6
Male
Myasthenia Gravis
Pilot Projects
Prognosis
Prospective Studies
Receptors, Tumor Necrosis Factor
authors with profiles
Matthew Meriggioli